Research News and Research

RSS

Positive results from preclinical EP-302 program presented at AACR 2010

Drug discovery and development company Esperance Pharmaceuticals today presented positive results from their preclinical EP-302 program that support the initiation of IND enabling studies. EP-302 is a targeted membrane-disrupting peptide designed to selectively kill cells that express nucleolin on their surface. Nucleolin is a protein that is over-expressed in a wide range of cancers and tumor endothelial cells.

22 Apr 2010

Hereditary ovarian cancer patients may develop secondary tumours in liver and spleen

Scientists have taken a major step forward in the understanding of ovarian cancer, which could improve treatment for patients with the condition.

22 Apr 2010

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced preclinical data which demonstrate that its Notch1-specific monoclonal antibody is a highly potent inhibitor of Notch1 function in both in vitro and in vivo models. These data were presented today at the American Association for Cancer Research (AACR) 101st Annual Meeting 2010 in Washington, D.C.

22 Apr 2010

Research findings may help personalize use of statins, scientists say

Researchers at NewYork-Presbyterian Hospital/Weill Cornell Medical Center have discovered why statins -- popular drugs that lower cholesterol and appear to protect against colorectal cancer development -- work for some people, but not for all.

22 Apr 2010

Miller-McCune: 'Existing beliefs' can stand in the way of medical research

After a scientist found that runners' widespread habit of using ibuprofen before long races didn't help them, and may even cause more inflammation than doing nothing, a group of runners presented with the evidence still said they would continue using the drug, reports Miller-McCune, a Santa Barbara-based public policy magazine. The researcher who conducted the study said, "They really, really think it's helping. … Even in the face of data showing that it doesn't help, they still use it."

22 Apr 2010

Patient-physician compatibility affects adherence to doctor's orders, patient's health status: Study

Doctors and patients have varying opinions on how much control a person has over their own health outcomes. A new study by University of Iowa researchers suggests that when doctor and patient attitudes on the issue match up, patients do a better job of taking their medications.

22 Apr 2010

University of Nevada professor awarded NIH RO1 grant for study of control of motility in internal anal sphincter

Kathleen Keef, Ph.D., professor of physiology and cell biology at the University of Nevada School of Medicine, has been awarded a four-year, $1.2 million grant from the National Institute of Health to study the control of motility in the internal anal sphincter.

22 Apr 2010

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

PharmaMar, a biopharmaceutical company owned by Grupo Zeltia (ZEL.MC), presented six new trials with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association for Cancer Research's (AACR) 101st Annual Meeting, held in Washington, D.C. from April 17-21.

22 Apr 2010

ImmunoCellular Therapeutics, UPENN sign research agreement

ImmunoCellular Therapeutics, Ltd., a biotechnology company that is developing immune based therapies for the treatment of various forms of cancer, announced today that the Company has entered into a sponsored research agreement and an option agreement with The University of Pennsylvania to support process development and manufacturing in a planned Phase II clinical trial of ICT-107, the Company's dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme.

22 Apr 2010

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

The US Food and Drug Administration (FDA) has approved Zortress® (everolimus) oral tablets for the prevention of rejection of kidney transplants in adult patients at low-to-moderate immunologic risk. Zortress is to be given in combination with reduced doses of the calcineurin inhibitor (CNI) cyclosporine, as well as basiliximab and corticosteroids.

22 Apr 2010

As more reform specifics emerge, so do questions, answers and impacts

As details of health reform policies shake out, questions, answers and consequences are emerging.

22 Apr 2010

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

Agios Pharmaceuticals, a biopharmaceutical company focused on discovering and developing novel drugs in the field of cancer metabolism, today announced multiple presentations at the American Association for Cancer Research (AACR) 101st Annual Meeting that highlight cancer metabolism as an approach to identify new ways to treat cancer, opening the potential for a new class of cancer drugs targeting metabolic enzymes.

22 Apr 2010

Children born very early have abnormal lung function: U.K. researchers

More than half of children who were born very early—at 25 weeks or less (normal gestation is around 40 weeks)— have abnormal lung function and are twice as likely as their full-term peers to have a diagnosis of asthma, according to U.K. researchers, who followed a national cohort of extremely preterm infants to age 11.

22 Apr 2010

SpectraCell Laboratories introduces apolipoprotein E genotyping

Effective immediately, SpectraCell Laboratories now offers apolipoprotein E genotyping. This test determines a person's genetic risk for heart disease associated with the commonly studied gene called apoE, which is involved in the metabolism of cholesterol and triglycerides (fats in the blood).

22 Apr 2010

Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR

Seattle Genetics, Inc. and Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., today reported preclinical data with ASG-5ME, an antibody-drug conjugate (ADC) that is being co-developed by both companies for the treatment of solid tumors. In models of human prostate and pancreatic cancer, ASG-5ME was found to have potent and long lasting antitumor activity. The findings were presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

22 Apr 2010

NO-naproxen blocks molecular changes leading to colorectal cancer development

Past randomized clinical trials have shown that non-steroidal anti-inflammatory drugs (NSAIDs), including naproxen, can reduce the risk of colon cancer and precancerous polyps in humans. Now, researchers at Fox Chase Cancer Center have found that an investigational form of naproxen, called nitric oxide-donating naproxen (NO-naproxen), can block one of the earliest molecular changes that lead to colorectal cancer development while also reducing gastrointestinal toxicity, a relatively common side effect associated with NSAIDs.

22 Apr 2010

Study links mutations in RAD51C gene to breast and ovarian cancer

The discovery 15 years ago that the genes BRCA1 and BRCA2 confer high risks for breast and ovarian cancer was a breakthrough for cancer prediction and therapy, especially for familial cases. Now the research group of Prof. Alfons Meindl (Klinikum rechts der Isar of the Technische Universitaet Muenchen), in collaboration with other groups from Germany, the U.K., and the U.S., can identify another gene that increases susceptibility to breast and ovarian cancer.

22 Apr 2010

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

Vaccines have been associated with painful injections for a very long time. In a new and important discovery researchers have developed special ‘nano patches’ that can deliver vaccines without needles in just two minutes using 100 times less dose than used conventionally.

22 Apr 2010

New Department of Neurosurgery for UNC School of Medicine

The University of North Carolina at Chapel Hill School of Medicine is establishing a new Department of Neurosurgery, effective July 1, 2010.

22 Apr 2010

Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer

Infinity Pharmaceuticals, Inc., an innovative drug discovery and development company, today announced that it has initiated a randomized Phase 1b/2 clinical trial evaluating IPI-926, its novel, oral Hedgehog pathway inhibitor, in combination with gemcitabine in patients with pancreatic cancer.

22 Apr 2010

Research News and Research

Positive results from preclinical EP-302 program presented at AACR 2010

Hereditary ovarian cancer patients may develop secondary tumours in liver and spleen

AVEO Pharmaceuticals presents data on potential utility of Notch1-specific monoclonal antibody at 101st AACR

Research findings may help personalize use of statins, scientists say

Miller-McCune: 'Existing beliefs' can stand in the way of medical research

Patient-physician compatibility affects adherence to doctor's orders, patient's health status: Study

University of Nevada professor awarded NIH RO1 grant for study of control of motility in internal anal sphincter

PharmaMar presents new trials with Yondelis, Zalypsis and Irvalec anti-tumor drugs at 101st AACR meeting

ImmunoCellular Therapeutics, UPENN sign research agreement

FDA approves Novartis Pharmaceuticals' Zortress for preventing rejection of kidney transplants

As more reform specifics emerge, so do questions, answers and impacts

Agios Pharmaceuticals presents data on cancer-associated IDH1 mutations at 101st AACR meeting

Children born very early have abnormal lung function: U.K. researchers

SpectraCell Laboratories introduces apolipoprotein E genotyping

Seattle Genetics, Agensys present ASG-5ME ADC preclinical data at 101st AACR

NO-naproxen blocks molecular changes leading to colorectal cancer development

Study links mutations in RAD51C gene to breast and ovarian cancer

No more needles for vaccines – a two minute Nanopatch may suffice, say researchers

New Department of Neurosurgery for UNC School of Medicine

Infinity Pharmaceuticals initiates Phase 1b/2 trial of IPI-926 Hedgehog pathway inhibitor for pancreatic cancer

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News